Table 2: Adapted from EACS guidelines 7.1 (Nov 2014) on adverse effects of antiretroviral therapy (ART) and drug classes.¹⁵
Frequent effects (events expected in a least 10% of treated HIV-positive persons) in bold. Severe effects (events that can put a person's life at risk and represent a medical emergency) in red. Neither frequent nor severe effects in black. (i) Frequency and severity differs between individual ARTs. (ii) Due to inhibition of renal tubular creatinine secretion without affecting glomerular filtration itself.

*Refers to effects seen in relation to hypersensitivity reactions. Note: the adverse effects included in the table above are not exhaustive, but represent the most important effects with a likely causal relation. Nausea, diarrhoea and rash are frequently observed in persons on ART, and these symptoms are indicated in the table for drugs where clinical experience suggests a possible causal link.

3TC, lamivudine; ABC, abacavir; ATV, atazanavir; BMD, bone mineral density; CV, cardiovascular; d4T, stavudine; ddl, didanosine; DRV, darunavir; DTG, dolutegravir; EFV, efavirenz; eGFR, estimated glomerular filtration rate; ENF, enfuvirtide; ETV, entecavir; EVG/COBI, elvitegravir/cobicistat; FPV, fosamprenavir; FTC, emtricitabine; HLA, human leukocyte antigen; IHD, ischaemic heart disease; IDV, idinavir; LPV, lopinavir; MVC, maraviroc; NVP, nevirapine; RAL, raltegravir; RPV, rilpirivine; SQV, saquinavir; TDF, tenofovir disoproxil fumarate; TPV, tipranavir; ZDV, zidovudine.